FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a monoclonal antibody or its antigen-binding fragment, which bind to MICA/B. Also disclosed is a pharmaceutical composition containing said antibody. Disclosed is the use of said antibody in a method of treating cancer associated with MICA/B expression.
EFFECT: invention makes it possible to effectively treat cancer which is associated with MICA/B expression.
8 cl, 7 ex, 1 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MICA/B ANTIBODIES BLOCKING MICA/B SHEDDING AND METHODS OF USE THEREOF | 2019 |
|
RU2815101C2 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| ANTIBODIES TO HUMAN NKG2D AND THEIR APPLICATION | 2008 |
|
RU2563343C2 |
| HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS | 2013 |
|
RU2628305C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| PROTEIN BOUND WITH HUMAN GLYCOPROTEIN, COMPOSITION, PHARMACEUTICAL COMPOSITION, EXPRESSION VECTOR | 2016 |
|
RU2773819C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| ISOLATED HUMANIZED PROTEIN BINDING TO HUMAN GLYCOPROTEIN VI, ISOLATED ANTIBODY BINDING TO HUMAN GLYCOPROTEIN VI | 2018 |
|
RU2778884C2 |
